RA CAPITAL MANAGEMENT, L.P. sold $254K of HOWL (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. sold 678,226 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.37 ($0.37–$0.38, $0.25M total) across 6 trades over 2026-06-09 to 2026-06-11.
How this was made
The 30-second read
Why it matters
A 10% owner’s open-market sale of ~$254k at ~$0.37–$0.38 can influence short-term sentiment and technical positioning, but it is not a fundamental update by itself.
Market read
Traders may reassess near-term risk for HOWL based on insider selling magnitude and timing, but without any new operational/clinical catalyst.
What to watch
No 10b5-1 plan is cited, so traders may over-interpret intent; also, the article provides no accompanying company news (trial, financing, or guidance) to confirm a thesis.
Background
The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics (HOWL).
Ticker impact
RA Capital Management (10% owner) sold 678,226 Werewolf Therapeutics shares in open-market trades at ~$0.37–$0.38, leaving 361,229 shares.
Mild-to-moderate downside bias over the next days/weeks, unless offset by new fundamentals.
The filing is a primary-source Form 4 showing a sizable open-market sale; however, it does not disclose a fundamental catalyst and may be consistent with routine liquidity/plan mechanics (noted as no 10b5-1 plan).
Market effects
Limited sector read-through; this is company-specific insider liquidity rather than a sector-wide regulatory/clinical signal.
None indicated; US microcap/biotech sentiment only.
None indicated.
Counterpoint
The sale may reflect diversification or liquidity needs rather than bearish fundamentals, especially since the trades span multiple days and are disclosed via Form 4.
Key entities
- issuerWerewolf Therapeutics, Inc.
Subject of the Form 4 insider sale; 10% owner RA Capital reduced holdings to 361,229 shares.
- insiderRA Capital Management, L.P.
10% owner who executed open-market sales across six trades (no 10b5-1 plan stated).
